<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04107675</url>
  </required_header>
  <id_info>
    <org_study_id>BT - L-CsA - 201 - SCT</org_study_id>
    <nct_id>NCT04107675</nct_id>
  </id_info>
  <brief_title>A Safety Study of Liposomal Cyclosporine A to Treat Bronchiolitis Obliterans Syndrome Following Allogeneic Hematopoietic Stem Cell Transplant</brief_title>
  <acronym>BOSTON-4</acronym>
  <official_title>A Phase IIa Multi-Center, Randomized, Single-Blind Safety Study of Liposomal Cyclosporine A to Treat Bronchiolitis Obliterans Syndrome Following Allogeneic Hematopoietic Stem Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Breath Therapeutics Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Breath Therapeutics Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase II prospective, multi-center, single-blind, randomized clinical trial of
      safety in the treatment of BOS 1 in adult recipients of an allogeneic hematopoetic stem cell
      transplant. Twenty-four patients are planned for enrollment. The clinical trial will be
      conducted in approximately 20 centers in Germany, France, and Spain. Patients will be
      randomly allocated 1:1:1 to receive either L-CsA (10 mg bid or 5 mg bid) plus Standard of
      Care, or liposomal placebo plus Standard of Care. Investigational Medicinal Product will be
      administered for up to 12 weeks.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Development of BOS after hematopoetic stem cell transplant (HSCT) is a major cause of
      morbidity and mortality; treatment options are limited and have not been optimized by
      well-conducted clinical trials. The hypothesis that local delivery of CsA by aerosol
      inhalation will achieve higher intrapulmonary concentration than by systemic administration
      alone, with limited toxicity compared to similar systemic doses due to minimal absorption of
      drug into the blood circulation has been substantiated by previous studies. The objectives of
      this study are to assess the tolerability, safety, PK, and exploratory efficacy of two dose
      levels of aerosolized L-CsA vs placebo in addition to SoC therapy for the treatment of BOS in
      adult allogeneic HSCT recipients.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 11, 2020</start_date>
  <completion_date type="Anticipated">January 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Investigational Medicinal Product Tolerability</measure>
    <time_frame>Baseline to Week 4</time_frame>
    <description>Change in FEV1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>through study completion, up to 3 years</time_frame>
    <description>Number of participants with treatment-related adverse events as assessed by CTCAE v4.0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hematology and Serum Chemistry Parameters</measure>
    <time_frame>through study completion, up to 3 years</time_frame>
    <description>Number of participants with treatment-related adverse events as assessed by CTCAE v4.0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital Signs</measure>
    <time_frame>through study completion, up to 3 years</time_frame>
    <description>Number of participants with treatment-related adverse events as assessed by CTCAE v4.0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigational Medicinal Product Tolerability</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Change in FEV1</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Peak Plasma Concentration (Cmax)</measure>
    <time_frame>Day 1 (after receiving the first dose of study drug)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Pharmacokinetic Parameters - CsA Levels</measure>
    <time_frame>Weeks 1, 4, 8, and 16</time_frame>
    <description>Whole Blood Trough Levels</description>
  </other_outcome>
  <other_outcome>
    <measure>FEV1 Percent Predicted</measure>
    <time_frame>Baseline through Week 16</time_frame>
    <description>Change in FEV1 percent predicted</description>
  </other_outcome>
  <other_outcome>
    <measure>FEV1/FVC</measure>
    <time_frame>Baseline through Week 16</time_frame>
    <description>Change in FEV1/FVC</description>
  </other_outcome>
  <other_outcome>
    <measure>Quality of Life Questionnaire</measure>
    <time_frame>Baseline through Week 8</time_frame>
    <description>The EuroQoL Health-related Quality of Life tool, Youth Version, is a dimple, generic measure of health.</description>
  </other_outcome>
  <other_outcome>
    <measure>Time to Peak Plasma Concentration (Tmax)</measure>
    <time_frame>Day 1 (after receiving the first dose of study drug)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Area Under the Plasma Concentration versus Time Curve (AUC)</measure>
    <time_frame>Day 1 (after receiving the first dose of study drug)</time_frame>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Bronchiolitis Obliterans</condition>
  <condition>GVHD, Chronic</condition>
  <condition>Stem Cell Transplant Complications</condition>
  <arm_group>
    <arm_group_label>L-CsA 10 mg plus Standard of Care</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Liposomal Cyclosporine A 10 mg bid for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>L-CsA 5 mg plus Standard of Care</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Liposomal Cyclosporine A 5 mg bid for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Liposomal Placebo plus Standard of Care</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Liposomal Placebo 2.5 mL bid for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liposomal Cyclosporine A</intervention_name>
    <description>Liposomal Cyclosporine A is administered with the PARI L-CsA eFlow Nebulizer.</description>
    <arm_group_label>L-CsA 10 mg plus Standard of Care</arm_group_label>
    <arm_group_label>L-CsA 5 mg plus Standard of Care</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liposomal Placebo</intervention_name>
    <description>Liposomal Placebo is administered with the PARI L-CsA eFlow Nebulizer.</description>
    <arm_group_label>Liposomal Placebo plus Standard of Care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age &gt;/= 18 years

          2. Patient must have a history of allogeneic HSCT, regardless of source of stem cell or
             donor or indication for allogeneic HSCT

          3. Documented diagnosis of chronic Graft versus Host Disease (cGvHD) in any organ other
             than the lung. If BOS is the only manifestation of cGvHD, lung biopsy must have been
             performed before entering the trial to confirm BOS diagnosis.

          4. Confirmed diagnosis of BOS Score 1 [Jagasia et al. 2015] within &gt; 6 months and &lt; 3
             years after allo-HSCT:

             FEV1/FVC &lt; 0.7 at Screening Visit AND Post-bronchodilator FEV1 &gt;/= 60 and â‰¤ 79%
             predicted at Screening Visit AND

               -  10% decline of FEV1 % predicted within 24 months prior to Screening Visit AND
                  Absence of acute infection in the respiratory tract.

          5. Patient must be capable of understanding the purposes and risks of the study, has
             given written informed consent, and agrees to comply with the study requirements.

          6. Patient is capable of aerosol inhalation.

          7. Women of childbearing potential must have a negative serum or urine pregnancy test at
             screening and at randomization visit.

        Exclusion Criteria:

          1. Active bacterial, viral (as confirmed by multiplex PCR) or fungal infection not
             successfully resolved at least 4 weeks prior to the Screening Visit.

          2. Chronic renal dysfunction with serum creatinine &gt;/= 2.5 mg/dL or need for renal
             dialysis.

          3. Chronic hepatic dysfunction with serum total bilirubin &gt; 5x upper limit of normal
             (ULN), transaminases &gt; 5x ULN, or alkaline phosphatase &gt; 5x ULN.

          4. Evidence of relapse of the primary malignancy which warranted allogeneic bone marrow
             transplant.

          5. Use of azithromycin within 4 weeks prior to Randomization (Visit 1).

          6. Use of zafirlukast during the study period.

          7. Chronic oxygen use or use of non-invasive ventilation.

          8. Active smokers (i.e. any kind of inhaled nicotine consumption).

          9. Pregnant women or women who are unwilling to use appropriate birth control to avoid
             pregnancy over the course of the clinical trial.

         10. Women who are currently breastfeeding.

         11. Known hypersensitivity to L-CsA or to cyclosporine A.

         12. Patients who do not tolerate administration of inhaled bronchodilators (e.g.,
             salbutamol).

         13. Patients with life-expectancy of less than 6 months.

         14. Treatments with other Investigational Medicinal Products (IMPs) or previous therapies
             within four weeks or five times half-life of the drug, whichever is longer prior to
             screening and during the study. Participation in registries, considering the before,
             is allowed.

         15. Psychiatric disorders or altered mental status precluding understanding of the
             informed consent process and/or completion of the necessary procedures.

         16. Any co-existing medical condition that in the Investigator's judgment will
             substantially increase the risk associated with the patient's participation in the
             clinical trial.

         17. Pre-scheduled hospitalizations, surgeries or interventions planned to be performed
             after obtaining Informed Consent for this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Noreen R Henig, MD</last_name>
    <role>Study Director</role>
    <affiliation>Breath Therapeutics - a Zambon Company</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stefanie Prante</last_name>
    <phone>+49 89 90405279</phone>
    <email>stefanie.prante@zambongroup.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU HÃ´pital Sud</name>
      <address>
        <city>Amiens</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Amandine Charbonnier, MD</last_name>
      <email>Charbonnier.amandine@chu-amiens.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire d'Angers</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frederic Gagnadoux, MD</last_name>
      <email>frgagnadoux@chu-angers.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Grenoble Alpes</name>
      <address>
        <city>La Tronche</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Thiebaut-Bertrand, MD</last_name>
      <email>athiebautbertrand@chu-grenoble.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier RÃ©gional Universitaire de Lille</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Leonardo Magro, MD</last_name>
      <email>leonardo.magro@chru-lille.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Nancy, Hopital Brabois</name>
      <address>
        <city>Nancy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie Detrait, MD</last_name>
      <email>m.detrait@chru-nancy.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Nantes - Hotel-Dieu</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrice Chevallier, MD</last_name>
      <email>patrice.chevallier@chu-nantes.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Saint Louis</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Bergeron, MD</last_name>
      <email>anne.bergeron-lafaurie@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Hopitaux de Bordeaux</name>
      <address>
        <city>Pessac</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Edouard Forcade, MD</last_name>
      <email>edouard.forcade@chu-bordeaux.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Henri Becquerel</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elodie Lhuillier, MD</last_name>
      <email>elodie.lhuillier@chb.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>St.-Johannes-Hospital</name>
      <address>
        <city>Dortmund</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ralf-Georg Meyer, MD</last_name>
      <email>ralf.meyer@oncoresearch.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UniversitÃ¤tsklinikum Carl Gustav Carus</name>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jan Moritz Middeke, MD</last_name>
      <email>janmoritz.middeke@uniklinikum-dresden.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UniversitÃ¤tsklinikum KÃ¶ln</name>
      <address>
        <city>KÃ¶ln</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Udo Holtick, MD</last_name>
      <email>udo.holtick@uk-koeln.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UniversitÃ¤tsklinikum Leipzig</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Vladan Vucinic, MD</last_name>
      <email>vladan.vucinic@medizin_uni_leipzig.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UniversitÃ¤tsklinikum MÃ¼nster</name>
      <address>
        <city>MÃ¼nster</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Matthias Stelljes, MD</last_name>
      <email>matthias.stelljes@ukmuenster.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic i Provincial</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carmen Martinez, MD</last_name>
      <email>cmarti@clinic.cat</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Irene Garcia-Cadenas, MD</last_name>
      <email>igarciaca@santpau.cat</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario RamÃ³n y Cajal</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anabelle Chinea, MD</last_name>
      <email>jljimenet@salud.madrid.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rafael Hernani-Morales, MD</last_name>
      <email>hernani_raf@gva.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari i PolitÃ¨cnic La Fe</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jaime Sanz, MD</last_name>
      <email>sanz_jai@gva.es</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>September 25, 2019</study_first_submitted>
  <study_first_submitted_qc>September 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 27, 2019</study_first_posted>
  <last_update_submitted>April 9, 2020</last_update_submitted>
  <last_update_submitted_qc>April 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bronchiolitis</mesh_term>
    <mesh_term>Bronchiolitis Obliterans</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

